Leadership
BreakBio Appoints MD Anderson Researcher Dr Greg Lizée as Chief Scientific Officer
By News Desk ·
Key takeaways
- Greg Lizée joined BreakBio as chief scientific officer from MD Anderson Cancer Center.
- Lizée led four clinical trials vaccinating more than 100 cancer patients.
- A Phase 1b NSCLC trial he worked on reported objective responses in seven of 24 patients.
BreakBio has appointed Greg Lizée, Ph.D., as chief scientific officer, the company said in a PR Newswire announcement dated November 19, 2026. Lizée joins BreakBio from The University of Texas MD Anderson Cancer Center, where he worked on tumor immunology, T-cell biology and therapeutic cancer vaccines.
Lizée's Vaccine Trial Record at MD Anderson
Lizée led four clinical trials that involved vaccinating more than 100 cancer patients, and he has authored or co-authored more than 100 peer-reviewed publications. His research covers identifying novel tumor antigens, designing personalized cancer vaccines and evaluating immune responses and immune suppression in patients.
His clinical work includes a Phase 1b personalized neoantigen vaccine trial in patients with advanced non-small cell lung cancer whose disease had progressed after multiple prior treatments. The study, published in 2021 in the Journal for ImmunoTherapy of Cancer, reported objective clinical responses in seven of 24 vaccinated patients, including six partial responses and one complete response among the 16 trial patients with mutant-EGFR NSCLC. Over the past decade Lizée also helped develop and run personalized cancer vaccine trials at MD Anderson in smoldering myeloma, pancreatic and colorectal cancers.
Roy de Souza, BreakBio's chief executive officer and co-founder, said: "Greg brings deep expertise in selecting tumor targets and designing vaccines to help the immune system recognize and attack cancer." De Souza added that Lizée's combination of scientific insight and clinical experience "will be invaluable as we advance BreakVax."
BreakBio's Clinical Program and Platform
According to akta.pro company records, BreakBio initiated enrollment for a Phase 1/2 clinical trial of its personalized peptide immunotherapy in triple negative breast cancer, with a 45-day biopsy-to-treatment manufacturing window. The same records describe an indication-agnostic platform designed to treat solid cancers by targeting each patient's unique mutations, and note that the company's Investigational New Drug application received FDA approval.
Stephen Hahn's Advisory Role and Clinic Entry
In October 2026, former FDA Commissioner Dr. Stephen Hahn joined BreakBio as an advisor to help shape its personalized cancer drug development, EIN Presswire reported. In August 2026, BreakBio said it would enter the clinic the following quarter, PR Newswire reported.
BreakVax Development
Lizée's experience will support BreakBio's development of BreakVax, a personalized peptide immunotherapy designed to help T cells recognize and attack each patient's cancer, according to the company's announcement.